The Role of hCG in Thawed Embryo Transfer

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07004192

Enrollment

220

Registered

2025-06-04

Start date

2025-06-02

Completion date

2027-12-31

Last updated

2025-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility (IVF Patients)

Keywords

Thawed embryo transfer

Brief summary

This prospective randomized trial will assess the relevance, if any, of a corpus luteum induced by hCG in transfers of thawed embryos.

Detailed description

The current study is designed to carefully isolate the effect of a corpus luteum by ensuring that the presence or absence of a corpus luteum is the only difference between two study arms. This should be reliably achieved by administering an injection of hCG in one study arm, while the other study arm has identical treatment except for omitting the hCG.

Interventions

DRUGHCG injection

5000 IU hCG injection

OTHERNo intervention

No hCG administered in this group.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

1. Female adult expecting to receive transfer of a thawed embryo. 2. At least one available frozen blastocyst of transferrable quality. 3. Non-menopausal female with at least one antral follicle. 4. Use of pre-implantation genetic testing (PGT), embryos derived from donor oocytes and/or donor sperm, a gestational carrier, and history of prior transfer(s) regardless of outcome are allowed. 5. Subsequent embryo transfers after failed transfers under this study are allowed, but not after a transfer that has resulted in ongoing pregnancy at ten weeks gestation under this study.

Exclusion criteria

1. Minors (age\<18 years). 2. Use of embryo(s) frozen at another center. 3. Patient insistent on transfer of two embryos. 4. Patient or partner unable to provide informed consent in English. 5. Patient already enrolled in any other research study for her embryo transfer. 6. History of anti-phospholipid syndrome or any other indication for use of Lovenox in pregnancy. 7. Patient for whom the physician assesses this protocol is inappropriate or unsafe.

Design outcomes

Primary

Measure	Time frame	Description
Blood pressure	Third trimester of pregnancy	Mean arterial pressure measured in third trimester of pregnancy

Countries

United States

Contacts

Primary ContactShironda Research Assistant

shironda@fertilitycenterlv.com702-254-1777

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026